{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:12:55Z","timestamp":1784031175536,"version":"3.55.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.beem.2024.101875","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T17:16:22Z","timestamp":1706116582000},"page":"101875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current role of pasireotide in the treatment of acromegaly"],"prefix":"10.1016","volume":"38","author":[{"given":"Salman Zahoor","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101875_bib1","doi-asserted-by":"crossref","unstructured":"Dopaminergic treatment of patients with acromegaly: still kicking after all these years. Archives in Endocrinology and Metabolism. 2022;66(3):275\u2013277.","DOI":"10.20945\/2359-3997000000502"},{"key":"10.1016\/j.beem.2024.101875_bib2","doi-asserted-by":"crossref","unstructured":"Yen S.S.C., Siler T.M., De Vane G.W. Effect of Somatostatin in Patients with Acromegaly. New England Journal of Medicine. 1974;290(17):935\u2013938.","DOI":"10.1056\/NEJM197404252901704"},{"issue":"9","key":"10.1016\/j.beem.2024.101875_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/0003-4819-117-9-711","article-title":"Octreotide Treatment of Acromegaly","volume":"117","year":"1992","journal-title":"Ann Intern Med"},{"issue":"25","key":"10.1016\/j.beem.2024.101875_bib4","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM198512193132504","article-title":"Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995","volume":"313","author":"Lamberts","year":"1985","journal-title":"N Engl J Med"},{"issue":"8406","key":"10.1016\/j.beem.2024.101875_bib5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(84)90706-2","article-title":"Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly","volume":"2","author":"Plewe","year":"1984","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.beem.2024.101875_bib6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib7","first-page":"145","article-title":"Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide","volume":"79","author":"Morange","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2024.101875_bib8","doi-asserted-by":"crossref","first-page":"R551","DOI":"10.1530\/ERC-16-0151","article-title":"Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future","volume":"23","author":"\u00d6berg","year":"2016","journal-title":"Endocr-Relat Cancer"},{"issue":"8","key":"10.1016\/j.beem.2024.101875_bib9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/archinte.1991.00400080073013","article-title":"Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group","volume":"151","author":"Vance","year":"1991","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR\u00ae (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib11","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2024.101875_bib12","first-page":"4099","article-title":"Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)","volume":"85","author":"Baldelli","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","article-title":"Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis","volume":"106","author":"Broersen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume":"156","author":"Taboada","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib15","first-page":"427","article-title":"Molecular biology of somatostatin receptors","volume":"16","author":"Reisine","year":"1995","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.beem.2024.101875_bib16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1471-4159.2004.02402.x","article-title":"Regulation and function of somatostatin receptors","volume":"89","author":"Olias","year":"2004","journal-title":"J Neurochem"},{"issue":"11","key":"10.1016\/j.beem.2024.101875_bib17","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/j.1582-4934.2010.01125.x","article-title":"Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways","volume":"14","author":"Cakir","year":"2010","journal-title":"J Cell Mol Med"},{"issue":"17","key":"10.1016\/j.beem.2024.101875_bib18","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/sj.emboj.7601279","article-title":"Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway","volume":"25","author":"Bousquet","year":"2006","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.beem.2024.101875_bib19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1179\/174313208X289499","article-title":"Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment","volume":"30","author":"Kurosaki","year":"2008","journal-title":"Neurol Res"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/eje.1.02213","article-title":"Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours","volume":"155","author":"Hubina","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.mce.2008.02.002","article-title":"Antitumor effects of somatostatin","volume":"286","author":"Pyronnet","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib22","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-05-1189","article-title":"Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression","volume":"66","author":"Theodoropoulou","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.beem.2024.101875_bib23","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/ijc.24602","article-title":"Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly","volume":"125","author":"Theodoropoulou","year":"2009","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to Somatostatin Analogs in Acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1210\/jc.2007-1986","article-title":"Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas","volume":"93","author":"Pl\u00f6ckinger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2024.101875_bib28","first-page":"2759","article-title":"Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity","volume":"84","author":"Barlier","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0950-351X(96)80378-8","article-title":"Endocrine disorders associated with mutations in guanine nucleotide binding proteins","volume":"10","author":"Milligan","year":"1996","journal-title":"Bailliere\u2019s Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2024.101875_bib30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1210\/jc.2003-031052","article-title":"A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients","volume":"89","author":"van der Hoek","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2024.101875_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro","volume":"94","author":"Lesche","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.beem.2024.101875_bib34","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1172\/JCI119779","article-title":"Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors","volume":"100","author":"Shimon","year":"1997","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.beem.2024.101875_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000054651","article-title":"Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro","volume":"73","author":"Tulipano","year":"2001","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/me.2009-0321","article-title":"Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways","volume":"24","author":"Cescato","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/me.2010-0398","article-title":"Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists","volume":"25","author":"Kao","year":"2011","journal-title":"Mol Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2024.101875_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib39","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1210\/jc.2003-031319","article-title":"The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion","volume":"89","author":"Murray","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","author":"Ib\u00e1\u00f1ez-Costa","year":"2016","journal-title":"J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib41","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2024.101875_bib42","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/en.2002-220219","article-title":"SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone\/insulin-like growth factor-I axis in rats, primates, and dogs","volume":"143","author":"Weckbecker","year":"2002","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib43","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas in Vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib44","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11102-013-0478-0","article-title":"Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study","volume":"17","author":"Petersenn","year":"2014","journal-title":"Pituitary"},{"issue":"7","key":"10.1016\/j.beem.2024.101875_bib46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1507\/endocrj.EJ16-0624","article-title":"Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study","volume":"64","author":"Tahara","year":"2017","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101875_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study","volume":"16","author":"Bronstein","year":"2016","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"10.1016\/j.beem.2024.101875_bib50","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101875_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00931","article-title":"Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs","volume":"10","author":"Gadelha","year":"2020","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","article-title":"Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study","volume":"62","author":"Shimon","year":"2018","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib54","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)","volume":"103","author":"Muhammad","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib55","first-page":"140","article-title":"BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas","volume":"86","author":"Saveanu","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib56","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib57","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib58","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2024.101875_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2024.101875_bib62","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2024.101875_bib63","doi-asserted-by":"crossref","first-page":"E1411","DOI":"10.1210\/jc.2012-1111","article-title":"Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway","volume":"97","author":"Chahal","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2024.101875_bib66","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr-Relat Cancer"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib67","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib68","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00330-018-5876-2","article-title":"Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI","volume":"29","author":"Kocak","year":"2019","journal-title":"Eur Radiol"},{"issue":"11","key":"10.1016\/j.beem.2024.101875_bib69","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00234-016-1728-4","article-title":"Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly","volume":"58","author":"Shen","year":"2016","journal-title":"Neuroradiology"},{"issue":"9","key":"10.1016\/j.beem.2024.101875_bib70","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2024.101875_bib71","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib72","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2008-1065339","article-title":"A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients","volume":"40","author":"Halperin","year":"2008","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib73","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ghir.2005.02.007","article-title":"Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly","volume":"15","author":"Biermasz","year":"2005","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/eje.1.01935","article-title":"Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly","volume":"153","author":"de Herder","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib75","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.2004.02191.x","article-title":"The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly","volume":"62","author":"Karavitaki","year":"2005","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2024.101875_bib76","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib77","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","article-title":"Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant","volume":"73","author":"Chiloiro","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib78","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12020-016-1182-4","article-title":"Safety and tolerability of pasireotide long-acting release in acromegaly\u2014results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study","volume":"55","author":"Fleseriu","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101875_bib79","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.beem.2024.101875_bib80","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib81","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12020-017-1386-2","article-title":"Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats","volume":"58","author":"Tarasco","year":"2017","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.beem.2024.101875_bib82","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib83","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","article-title":"Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly","volume":"53","author":"Schmid","year":"2016","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.beem.2024.101875_bib84","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2024.101875_bib85","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"10215","key":"10.1016\/j.beem.2024.101875_bib86","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","article-title":"Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the multinational cardiovascular risk consortium","volume":"394","author":"Brunner","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib87","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.beem.2024.101875_bib88","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary"},{"issue":"8","key":"10.1016\/j.beem.2024.101875_bib89","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/jc.2008-0315","article-title":"Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial","volume":"93","author":"Carlsen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib90","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1530\/EJE-09-0908","article-title":"Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial","volume":"162","author":"Mao","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2024.101875_bib91","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.beem.2024.101875_bib92","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2024.101875_bib93","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101875_bib94","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.beem.2024.101875_bib95","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management of endocrine disease: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2024.101875_bib96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:47:37Z","timestamp":1721342857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1521690X24000174"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101875","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current role of pasireotide in the treatment of acromegaly","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101875"}}